Psoriasis Clinical Trials in Seattle
View 16 new treatments for Psoriasis in Seattle, WA, and nearby areas, such as Bellevue, Everett, Kent and Renton. Every day, Power helps hundreds of psoriasis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Bellevue + 4 more
The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Waitlist
Phase 4
Est. 3 - 6 Weeks
Bristol-Myers Squibb
Study Director
Guselkumab for Psoriatic Arthritis
Janssen Clinic, Seattle + 1 more
This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 5 - 8 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Mill Creek + 2 more
The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.Show More
Recruiting
Phase 4
Est. 5 - 8 Weeks
Bristol-Myers Squibb
Study Director
Apremilast for Pediatric Plaque Psoriasis
Amgen Clinic, Mill Creek + 1 more
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
MD
Study Director
Upadacitinib for Psoriatic Arthritis
AbbVie Clinic, Seattle + 1 more
The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo for the treatment of signs and symptoms in adults with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to biologic disease-modifying anti-rheumatic drug (bDMARD). The objective of Period 2 is to evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in participants who have completed Period 1.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
AbbVie Inc.
Study Director
Deucravacitinib for Psoriatic Arthritis
Bristol-Myers Squibb Clinic, Bothell + 2 more
This trial is testing a new medication called deucravacitinib to see if it can help people with psoriatic arthritis who haven't tried advanced treatments. The medication works by reducing joint swelling and pain by blocking inflammation. Deucravacitinib is a new oral drug that has shown good results in previous studies for psoriasis.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director
Certolizumab Pegol for Plaque Psoriasis
UCB Biopharma Clinic, Seattle + 1 more
The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12 to 17 years.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
UCB Cares
Study Director
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Seattle + 2 more
The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director
JNJ-77242113 for Plaque Psoriasis
Janssen Clinic, Mill Creek + 1 more
This trial is testing a new medication called JNJ-77242113 to see if it helps people with moderate to severe plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches. The study aims to find out if this new treatment can improve symptoms for those who have not responded well to other treatments.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Ixekizumab + Tirzepatide for Psoriasis
Eli Lilly Clinic, Bellevue + 2 more
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Page 1 of 2
Frequently Asked Questions
Explore related conditions